Furthermore, inhibitors of mTOR were less successful in clinical studies in the treatment of B cell lymphomas than expected based on pre-clinical experiments [21], suggesting the need for multi-target approaches that include inhibitors of mTOR in conjunction with HIF-1α. The gene discussed is HIF1A; the disease is B-cell non-Hodgkin lymphoma.